Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

Bardia et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69d78dca5f9a1dad534907e8 — DOI: https://doi.org/10.1056/nejmoa1814213

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Clinical and pharmacogenetic factors associated with irinotecan toxicity· 2008 · 96 citations
2. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer· 2010 · 88 citations
3. FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma· 2017 · 88 citations
4. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer· 2012 · 3,753 citations
5. The epidemiology of triple-negative breast cancer, including race· 2009 · 340 citations